Search Result

Results for "

Prostacyclin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenylate Cyclase (2) Akt (2) Angiotensin Receptor (1) Antibiotic (2) Apoptosis (2) Bacterial (3) Calcium Channel (1) Carnitine Palmitoyltransferase (CPT) (1) Drug Derivative (2) Drug Isomer (1) Drug Metabolite (4) Endogenous Metabolite (7) Estrogen Receptor/ERR (1) Integrin (1) Isotope-Labeled Compounds (5) mTOR (2) nAChR (1) PDGFR (2) Phosphodiesterase (PDE) (2) PPAR (3) Prostaglandin Receptor (50) PTEN (2) Reactive Oxygen Species (ROS) (1) Reference Standards (11) SARS-CoV (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (49) Endocrinology (17) Infection (3) Inflammation/Immunology (11) Metabolic Disease (6) Neurological Disease (8)

By Targets:

Adenylate Cyclase (2)

Akt (2)

Angiotensin Receptor (1)

Antibiotic (2)

Apoptosis (2)

Bacterial (3)

Calcium Channel (1)

Carnitine Palmitoyltransferase (CPT) (1)

Drug Derivative (2)

Drug Isomer (1)

Drug Metabolite (4)

Endogenous Metabolite (7)

Estrogen Receptor/ERR (1)

Integrin (1)

Isotope-Labeled Compounds (5)

mTOR (2)

nAChR (1)

PDGFR (2)

Phosphodiesterase (PDE) (2)

PPAR (3)

Prostaglandin Receptor (50)

PTEN (2)

Reactive Oxygen Species (ROS) (1)

Reference Standards (11)

SARS-CoV (1)

By Research Areas:

Cancer (8)

Cardiovascular Disease (49)

Endocrinology (17)

Infection (3)

Inflammation/Immunology (11)

Metabolic Disease (6)

Neurological Disease (8)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-A0096

Iloprost 5 Publications Verification Ciloprost; ZK 36374	Prostaglandin Receptor Endogenous Metabolite	Cardiovascular Disease Endocrinology Cancer
Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research .

HY-14870

Selexipag 3 Publications Verification NS-304; ACT-293987	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI₂) receptor (IP receptor).

HY-A0126A

Epoprostenol sodium 1 Publications Verification Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan	Endogenous Metabolite Apoptosis	Cardiovascular Disease
Epoprostenol sodium (Prostaglandin I2) sodium salt, the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH). Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .

HY-124124

N-Methylnicotinamide 1 Publications Verification	Endogenous Metabolite Drug Metabolite	Cardiovascular Disease Metabolic Disease Cancer
N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway .

HY-108912

RO1138452 CAY10441	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
RO1138452 is a potent and selective IP (prostacyclin) receptor antagonist. RO1138452 displays high affinity for IP receptors. In human platelets, pK_i is 9.3±0.1; in a recombinant IP receptor system, pK_i is 8.7±0.06.

HY-16751

Ralinepag APD811	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Ralinepag is a potent, orally bioavailable and non-prostanoid prostacyclin (IP) receptor agonist, with EC₅₀s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.

HY-13569A

Beraprost sodium TRK-100; ML 1129 sodium	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
Beraprost sodium (TRK-100), a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium (TRK-100) is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation . Beraprost sodium (TRK-100) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-B0428

Ozagrel 1 Publications Verification OKY-046	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel (OKY-046) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA₂ and increasing the production of prostacyclin (PGI2). Ozagrel can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-B1016

Trapidil AR-12008	PDGFR Phosphodiesterase (PDE) Prostaglandin Receptor	Cardiovascular Disease Neurological Disease
Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A₂ synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury .

HY-N6043

Hydroxytyrosol acetate	Apoptosis Reactive Oxygen Species (ROS) Bacterial SARS-CoV Estrogen Receptor/ERR	Infection Neurological Disease Inflammation/Immunology
Hydroxytyrosol acetate is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol acetate not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol acetate effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol acetate significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol acetate has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .

HY-106961

ONO 1301 ONO-AP 500-02	Prostaglandin Receptor	Cardiovascular Disease
ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting *prostacyclin* agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .

HY-128932

Cefminox sodium 1 Publications Verification MT-141	Antibiotic Bacterial PPAR Prostaglandin Receptor PTEN Akt mTOR	Infection Cardiovascular Disease Endocrinology
Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits antibacterial activity. Cefminox sodium is a broad-spectrum, bactericidal cephalosporin antibiotic. Cefminox sodium also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ. Cefminox sodium upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium also prevents pulmonary arterial hypertension in rat model .

HY-B0428B

Ozagrel hydrochloride 1 Publications Verification OKY-046 hydrochloride	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA₂ and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-106961A

(Z)-ONO 1301 (Z)-ONO-AP 500-02	Prostaglandin Receptor	Cardiovascular Disease
(Z)-ONO 1301 is the isomer of ONO 1301 (HY-106961), and can be used as an experimental control. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting *prostacyclin* agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .

HY-118941

BAY 73-1449	Prostaglandin Receptor	Cardiovascular Disease
BAY 73-1449 is a selective antagonist of prostacyclin receptor (IP), with high potency (IC₅₀ of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG. BAY 73-1449 can be used in the research of lowering blood pressure .

HY-112322

Carbacyclin 1 Publications Verification CarbaProstacyclin; Carba-PGI2	PPAR Prostaglandin Receptor Carnitine Palmitoyltransferase (CPT)	Cardiovascular Disease Metabolic Disease
Carbacyclin is a PGI2 analogue, acts as a prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation.

HY-128039

17-Phenyl-ω-trinor-PGE2	Prostaglandin Receptor	Others
17-Phenyl-ω-trinor-PGE2 is a PGE2 (HY-101952) analog, which is an agonist for EP1 and EP3 receptor. 17-Phenyl-ω-trinor-PGE2 inhibits the PAF-induced aggregation of human platelet-rich plasma (PRP) and Cicaprost (HY-19583) induced Cyclic AMP (HY-B1511) production .

HY-124124S

N-Methylnicotinamide-d4	Isotope-Labeled Compounds Endogenous Metabolite Drug Derivative	Cardiovascular Disease Metabolic Disease Cancer
N-Methylnicotinamide-d₄ is the deuterium labeled N-Methylnicotinamide (HY-124124). N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway.

HY-B0428A

Ozagrel sodium 1 Publications Verification OKY-046 sodium	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA₂ and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-108565

BMY 45778	Adenylate Cyclase Prostaglandin Receptor	Cardiovascular Disease
BMY 45778 is a non-prostanoid prostacyclin mimetic. BMY 45778 inhibits human (IC₅₀ = 35 nM), rabbit (IC₅₀: 136 nM) and rat (IC₅₀ : 1.3 μM) platelet aggregation. BMY 45778 also activates adenylyl cyclase. BMY 45778 is a partial agonist at the prostacyclin receptor .

HY-164580

RO3244794	Prostaglandin Receptor	Neurological Disease Inflammation/Immunology
RO3244794 is a potent and selective *IP (prostacyclin) receptor* antagonist, with a pK_i of 7.7 and 6.9 in human platelet and recombinant IP receptor system, respectively. RO3244794 exhibits analgesic and anti-inflammatory potential .

HY-A0096R

Iloprost (Standard) Ciloprost (Standard); ZK 36374 (Standard)	Reference Standards Prostaglandin Receptor Endogenous Metabolite	Endocrinology Cancer
Iloprost (Standard) is the analytical standard of Iloprost. This product is intended for research and analytical applications. Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research .

HY-114671

Taprostene CG-4203	Prostaglandin Receptor	Cardiovascular Disease
Taprostene (CG-4203) is a synthetic, chemically stable analogue of *Prostacyclin* (PGI2). Taprostene exhibits endothelium and myocardial protecting actions after acute myocardial ischemia and reperfusion in cats. Taprostene enhances cytoprotective actions, while minimizing unwanted hemodynamic effects .

HY-14870S3

Selexipag-d6 NS-304-d₆; ACT-293987-d₆	Isotope-Labeled Compounds Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Selexipag-d₆ is deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor).

HY-14870S1

Selexipag-d7	Isotope-Labeled Compounds Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Selexipag-d₇ is the deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor) .

HY-A0096S

Iloprost-d4	Isotope-Labeled Compounds Prostaglandin Receptor	Endocrinology
Iloprost-d₄ (Ciloprost-d₄) is the deuterium labeled Iloprost. Iloprost (ZK 36374) is a synthetic analogue of prostacyclin PGI2 .

HY-14870R

Selexipag (Standard) NS-304 (Standard); ACT-293987 (Standard)	Reference Standards Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Selexipag (Standard) is the analytical standard of Selexipag. This product is intended for research and analytical applications. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI₂) receptor (IP receptor).

HY-173420

15-Keto Iloprost	Drug Derivative	Cardiovascular Disease Endocrinology Cancer
15-Keto Iloprost is a C-15 oxidized derivative of Iloprost (HY-A0096). Iloprost (ZK 36374) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis .

HY-112079

NPC-15669	Integrin	Cardiovascular Disease
NPC-15669 is a novel Mac-1 inhibitor. NPC-15669 reduces plasma levels of ET-1, TxB, prostacyclin, AT-III, and total protein S. NPC-15669 can be used in the research of myocardial infarction .

HY-108912R

RO1138452 (Standard) CAY10441 (Standard)	Prostaglandin Receptor Reference Standards	Inflammation/Immunology Endocrinology
RO1138452 (Standard) is the analytical standard of RO1138452. This product is intended for research and analytical applications. RO1138452 is a potent and selective IP (prostacyclin) receptor antagonist. RO1138452 displays high affinity for IP receptors. In human platelets, pKi is 9.3±0.1; in a recombinant IP receptor system, pKi is 8.7±0.06.

HY-13569AR

Beraprost sodium (Standard) TRK-100 (Standard); ML 1129 sodium (Standard)	Reference Standards Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
Beraprost (sodium) (Standard) is the analytical standard of Beraprost (sodium). This product is intended for research and analytical applications. Beraprost sodium, a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation . Beraprost (sodium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-B1016R

Trapidil (Standard) AR-12008 (Standard)	Reference Standards PDGFR Phosphodiesterase (PDE) Prostaglandin Receptor	Cardiovascular Disease Cancer
Trapidil (Standard) (AR-12008 (Standard)) is the analytical standard of Trapidil (HY-B1016R). This product is intended for research and analytical applications. Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A2 synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury.

HY-127162

Prostaglandin K1 PGK1	Prostaglandin Receptor	Others
Prostaglandin K1 (compound 46) is a structurally modified analog of prostacyclin (prostanoid) with an EC₅₀ of 2800 nM for EP1 and a K_i of 2800 nM .

HY-114587

RS 93427-007	Prostaglandin Receptor	Cardiovascular Disease
RS 93427-007 is an orally active prostacyclin stable mimetic agent. RS 93427-007 can be used for the research of cardiovascular disease, such as atherosclerosis .

HY-120309

BMY 42393	Prostaglandin Receptor	Cardiovascular Disease
BMY 42393 is an orally active *prostacyclin* agonist which suppresses monocyte-macrophage atherogenic activity and cytokine production. BMY 42393 can be used for atherosclerosis research .

HY-A0126AR

Epoprostenol sodium (Standard) Prostaglandin I2 sodium salt (Standard); Prostacyclin sodium salt (Standard); Flolan (Standard)	Reference Standards Endogenous Metabolite	Cardiovascular Disease
Epoprostenol (sodium) (Standard) is the analytical standard of Epoprostenol (sodium). This product is intended for research and analytical applications. Epoprostenol sodium (Prostaglandin I2 (sodium salt)), the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH) . Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .

HY-160993

Ciprostene 9β-Methylcarbacyclin	Prostaglandin Receptor	Cardiovascular Disease
Ciprostene is analog of prostacyclin (PGI2). Ciprostene inhibits adenosine diphosphate-induced platelet aggregation. Ciprostene can be used for research of peripheral vascular disease .

HY-122499

Ciprostene calcium	Prostaglandin Receptor	Cardiovascular Disease
Ciprostene calcium is a prostacyclin analogue.Ciprostene calcium inhibits adenosine diphosphate-induced platelet aggregation. Ciprostene calcium can be used for research of peripheral vascular disease .

HY-142972

19(S)-HETE	Prostaglandin Receptor	Cardiovascular Disease
19(S)-HETE is an arachidonic acid metabolite produced by cytochrome P450 enzymes. 19(S)-HETE is a full orthosteric agonist of the prostacyclin (IP) receptor with an EC₅₀ value of 567 nM. 19(S)-HETE inhibits platelet activation and relaxation of vessels .

HY-106110

OP-2507	Prostaglandin Receptor	Metabolic Disease
OP-2507 is a prostacyclin analog. OP-2507 can increase brain glucose levels in mice, suppress the breakdown of energy metabolism under hypoxic conditions, and has a protective effect against changes in cyclic nucleotides in hypoxic brain tissue (specifically, an increase in cyclic AMP and a decrease in cyclic GMP). OP-2507 provides protective effects against brain hypoxia and edema .

HY-123293

UK 34787	Prostaglandin Receptor	Cardiovascular Disease
UK 34787 is a selective thromboxane synthetase inhibitor with little or no activity against cyclooygenase or prostacyclin synthetase .

HY-167091

(Rac)-Beraprost (Rac)-TRK-100 free acid; (Rac)-ML 1229	Prostaglandin Receptor	Cardiovascular Disease
(Rac)-Beraprost ((Rac)-ML 1229) is an orally active prostacyclin analog that inhibits the release of Ca ²⁺ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis .

HY-Z7721

(Rac)-Beraprost sodium (Rac)-TRK-100; (Rac)-ML 1129 sodium	Prostaglandin Receptor	Cardiovascular Disease
(Rac)-Beraprost ((Rac)-ML 1129) sodium is a racemic isomer of Beraprost sodium (HY-13569A). Beraprost sodium is an orally active prostacyclin analog that inhibits the release of Ca ²⁺ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost sodium has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis .

HY-105315

AFP-07	Prostaglandin Receptor	Endocrinology
AFP-07 is a derivative of 7, 7-difluoroprostacyclic and is a highly potent and selective prostacyclin receptor IP receptor agonist with a K_i value of 0.561 nM .

HY-166363S

Beraprost-d3 TRK-100-d₃; ML 1129-d₃	Isotope-Labeled Compounds Prostaglandin Receptor	Cardiovascular Disease
Beraprost-d₃ (TRK-100-d₃) is deuterium labeled (Rac)-Beraprost. (Rac)-Beraprost ((Rac)-ML 1229) is an orally active prostacyclin analog that inhibits the release of Ca ²⁺ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis .

HY-129293

AFP-07 free acid	Prostaglandin Receptor	Endocrinology
AFP-07 free acid is a derivative of 7, 7-difluoroprostacyclic and is a highly potent and selective prostacyclin receptor IP receptor agonist with a K_i value of 0.561 nM .

HY-106699

Taprostene sodium CG 4203 sodium	Prostaglandin Receptor nAChR	Cardiovascular Disease
Taprostene sodium is a partial agonist at prostanoid prostacyclin (IP) receptors. Taprostene sodium interacts additively with Prostaglandin E2 (PGE2) (HY-101952), ONO-AE1-259 (selective EP2 agonist), and acetylcholine. Taprostene sodium exerts a significant cardioprotection .

HY-124124R

N-Methylnicotinamide (Standard)	Reference Standards Endogenous Metabolite Drug Metabolite	Cardiovascular Disease Metabolic Disease Cancer
N-Methylnicotinamide (Standard) is the analytical standard of N-Methylnicotinamide (HY-124124). This product is intended for research and analytical applications. N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway.

HY-137227

15(R)-PTA2 15(R)-Pinanethromboxane A2	Prostaglandin Receptor	Cardiovascular Disease
15(R)-PTA2 (15(R)-Pinanethromboxane A2) is an antithrombotic agent that inhibits platelet aggregation. 15(R)-PTA2 inhibits stable prostaglandin endoperoxide analog-induced constriction of feline coronary arteries and stabilizes hepatic lysosomes. 15(R)-PTA2 also inhibits thromboxane synthase but has no effect on prostacyclin synthase .

HY-173419

5-cis-15(R)-Iloprost 5-cis-15(R)-Ciloprost; 5-cis-15(R)-ZK 36374	Drug Isomer Prostaglandin Receptor	Endocrinology Cancer
5-cis-15(R)-Iloprost (5-cis-15(R)-Ciloprost) is the C-5 cis-isomer and 15(R)-epimer of Iloprost (HY-A0096). Iloprost is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research .

Cat. No.	Product Name	Target	Research Area

HY-P0216A

A-779 TFA	Angiotensin Receptor	Cardiovascular Disease
A-779 TFA is a selective angiotensin-(1-7) (Ang-(1-7)) antagonist. A-779 TFA blocks Arachidonic acid release, bradykinin potentiation effects and hypotensive action. A-779 TFA exerts diuretic effects in non-pregnant rats, antidiuretic effects in late-pregnant rats, and also inhibits feed intake and water consumption in late-pregnant rats. A-779 TFA attenuates the regulatory effects of prostacyclin, nitric oxide and thromboxane A₂ associated with angiotensin-(1-7). A-779 TFA can be used in studies related to hypertension .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-A0096

Iloprost 5 Publications Verification Ciloprost; ZK 36374	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Endocrinology Source Classification Cancer	Prostaglandin Receptor Endogenous Metabolite
Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research .

HY-A0126A

Epoprostenol sodium 1 Publications Verification Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Apoptosis
Epoprostenol sodium (Prostaglandin I2) sodium salt, the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH). Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .

HY-124124

N-Methylnicotinamide 1 Publications Verification	Alkaloids Structural Classification Classification of Application Fields Pyridine Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Drug Metabolite
N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway .

HY-N6043

Hydroxytyrosol acetate	Structural Classification Canarium album (Lour.) Rauesch. Classification of Application Fields Phenols Polyphenols Plants Burseraceae Inflammation/Immunology Disease Research Fields Source Classification	Apoptosis Reactive Oxygen Species (ROS) Bacterial SARS-CoV Estrogen Receptor/ERR
Hydroxytyrosol acetate is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol acetate not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol acetate effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol acetate significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol acetate has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .

HY-A0096R

Iloprost (Standard) Ciloprost (Standard); ZK 36374 (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Prostaglandin Receptor Endogenous Metabolite
Iloprost (Standard) is the analytical standard of Iloprost. This product is intended for research and analytical applications. Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research .

HY-124124R

N-Methylnicotinamide (Standard)	Alkaloids Structural Classification Pyridine Alkaloids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Drug Metabolite
N-Methylnicotinamide (Standard) is the analytical standard of N-Methylnicotinamide (HY-124124). This product is intended for research and analytical applications. N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway.

HY-133941

2,3-Dinor-6-keto-prostaglandin F1α 2,3-Dinor-6-keto-PGF1α	Structural Classification Endogenous metabolite Lipid Source Classification	Drug Metabolite
2,3-Dinor-6-keto-prostaglandin F1α (2,3-Dinor-6-keto-PGF1α) is the major urinary metabolite of Prostaglandin I₂ (HY-A0126A). 2,3-Dinor-6-keto-prostaglandin F1α is applicable to the research of coronary heart disease .

Cat. No.	Product Name	Chemical Structure

HY-124124S

N-Methylnicotinamide-d4

N-Methylnicotinamide-d₄ is the deuterium labeled N-Methylnicotinamide (HY-124124). N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway.

HY-14870S3

Selexipag-d6
Selexipag-d₆ is deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor).

HY-14870S1

Selexipag-d7
Selexipag-d₇ is the deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor) .

HY-A0096S

Iloprost-d4
Iloprost-d₄ (Ciloprost-d₄) is the deuterium labeled Iloprost. Iloprost (ZK 36374) is a synthetic analogue of prostacyclin PGI2 .

HY-166363S

Beraprost-d3

Beraprost-d₃ (TRK-100-d₃) is deuterium labeled (Rac)-Beraprost. (Rac)-Beraprost ((Rac)-ML 1229) is an orally active prostacyclin analog that inhibits the release of Ca ²⁺ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis .

Host:	Rabbit (2)
Reactivity:	Human (2) Rat (2) Mouse (2)
Application:	IHC-P (2) ICC/IF (2) IHC-F (2) WB (2)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (1) Recombinant (1)
Modification:	Unmodified (1)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83334

	IGFBP7 Antibody (YA3079) IGFBP7; MAC25; PSF; Insulin-like growth factor-binding protein 7; IBP-7; IGF-binding protein 7; IGFBP-7; IGFBP-rP1; MAC25 protein; PGI2-stimulating factor; Prostacyclin-stimulating factor; Tumor-derived adhesion factor; TAF	WB, IHC-F, IHC-P, ICC/IF	Human, Mouse, Rat
	IGFBP7 Antibody (YA3079) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IGFBP7.

HY-P83334A

	IGFBP7 Antibody (YA3079)(PBS only) IGFBP7; MAC25; PSF; Insulin-like growth factor-binding protein 7; IBP-7; IGF-binding protein 7; IGFBP-7; IGFBP-rP1; MAC25 protein; PGI2-stimulating factor; Prostacyclin-stimulating factor; Tumor-derived adhesion factor; TAF	WB, IHC-F, IHC-P, ICC/IF	Human, Mouse, Rat
	IGFBP7 Antibody (YA3079) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IGFBP7.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks